Navigation Links
A Biologic Drug Superior to Spiriva in Reducing COPD-Related Exacerbations Would Earn a Higher Patient Share in Europe Than in the U.S.

Spiriva Will Remain the Gold Standard Treatment Through 2017, According to a New Report from Decision Resources.

WALTHAM, Mass., Jan. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a biologic drug that is superior to Boehringer Ingelheim/Pfizer's Spiriva in reducing yearly COPD-related exacerbations would earn a higher patient share in Europe (30 percent) than in the U.S. (15 percent) according to surveyed European and U.S. pulmonologists. COPD-related exacerbations are episodic events often requiring hospitalization.

"A biological drug that provides fewer yearly COPD-related exacerbations compared to current therapies holds much commercial promise," said Regina Jammen, M.S., analyst at Decision Resources. "Enthusiasm from U.S. and European pulmonologists for a biologic drug with the potential to dramatically reduce yearly exacerbation rates likely reflects physicians' recognition of not only the long-term therapeutic benefits of such a drug, but also its economic benefits."

The new report entitled Chronic Obstructive Pulmonary Disease: Blockbuster Potential Exists for Biologic Drugs That Dramatically Reduce Exacerbation Rates finds that Spiriva will remain Decision Resources' clinical gold standard treatment for COPD over the next eight years even though emerging drugs such as Forest/Almirall's aclidinium, Novartis's indacaterol, Boehringer Ingelheim's BI-1744/tiotropium and Nycomed/Mitsubishi Tanabe's roflumilast will offer therapeutic benefits to COPD patients.

About the Report

Chronic Obstructive Pulmonary Disease: Blockbuster Potential Exists for Biologic Drugs That Dramatically Reduce Exacerbation Rates is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( ) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at .

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563            

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biologic treatment for rheumatoid arthritis and the risk of cancer
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Neurobiological Technologies Reports Going Concern Qualification
4. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
5. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
6. Study questions assumptions about human sensitivity to biological motion
7. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
8. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
9. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
10. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
11. CalbaTech Reports That LifeStems Biologics License Has Been Renewed
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... with autism, PediaPlex , a Southlake, Texas, child development and pediatric therapy ... and educating military families about their options for receiving this kind of ...
(Date:10/13/2015)... ... October 13, 2015 , ... Just under three months ago, ... Concepts began a $1 promotion – effectively offering all of their services for just ... weeks the company was flooded with phone calls from interested buyers. As a genuine ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... Women’s show this coming October in Toronto, an exhibition featuring the newest products ... choose from, Curly Hair Solutions® couldn’t be more excited to unveil their recent ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... solutions for drugs, biologics, consumer health and animal health products, today announced that ... lead a new, dedicated global team of drug development and technology experts. , ...
(Date:10/12/2015)... ... October 13, 2015 , ... ... to announce the release of its new Professional Medical Coding and Billing with ... both the ICD-10-CM and ICD-10-PCS code sets, earn the Certified Professional Coder (CPC) ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... -- About epilepsy --> ... disorders manifested by benign to severe, disabling, and life-threatening ... malformations and tumors to meningitis, high-risk pregnancies, and trauma ... is unidentified, as is witnessed in the majority of ... between the inhibitory and excitatory signals of the brain, ...
(Date:10/12/2015)... Elbit Imaging Ltd. ("EI" or the ... board of directors approved a program to repurchase up to ... H Notes and Series I Notes, which are traded on ... the Company will have a significant preference to the purchase ... to time in the open market on the Tel Aviv ...
(Date:10/12/2015)... , Oct. 12, 2015 A new computer ... children can predict whether they will develop effective language ... to a study in the journal Brain and ... --> In the journal,s Oct. 12 online edition, ... computer program determines how specific regions of the brain ...
Breaking Medicine Technology: